Gate2Brain Obtains 2.5M from Europe to Advance Against Brain Tumors

Economic accolade for Gate2Brain. The Spanish biotech company, which develops technology for brain tumors, has raised €2.5 million from the European Commission, through the EIC Accelerator program.

Specifically, the spin-off of the University of Barcelona (UB), the Barcelona Biomedical Research Institute (IRB Barcelona), and the San Joan de Déu Hospital have received these funds that will allow them to develop their treatment that facilitates the arrival of medicines to the brain to face, among other pathologies, childhood cancer.

The help of EIC Accelerator will allow Gate2Brain to boost its proprietary technology based on peptides (small proteins) that cross biological barriers and reach the brain. These peptides can tow drugs that, on their own, cannot reach the brain to cure it.

Read more about Gate2Brain and its recent financing round and find other important news in the sector, with our companion app. Born2Invest is a digital media website covering the biotech industry, among others. Our companion app allows you to get your daily dose of financial news from industries like banking, cannabis, and innovation in biotechnology.

Gate2Brain expects to be able to carry out a clinical trial in two years

The company is confident that the funds can boost the preclinical phase of its drug G2B-002, which is aimed at barrier-intact brain tumors, which it is carrying out in collaboration with the Hospital San Joan de Déu. In two years, the results could lead to a clinical trial.

At the beginning of 2022, the Spanish biotech company received a grant of €300,000 from La Caixa, through the CaixaResearch Consolidate call, to finance part of the preclinical trials of its first therapy.

Gate2Brain was created in 2020 by Meritxell Teixidó. The business project received support from the Botín Foundation’s Mind the Gap program to establish itself, with an investment of €500,000 and support through the incorporation of an expert who supports the entrepreneurial team, as well as a grant of €100,000 from the BStartup Health program of Banc Sabadell shortly after its incorporation.

The company has received funding from the Botín Foundation and BStartup

The Gate2Brain team’s research is relevant for families with minors affected by this brain tumor, which develops between five and six years of life, mainly with a short life expectancy.

The indication of Gate2Brain’s biotechnology has focused on this type of childhood brain tumor, but in the future, it may also be applied to other pathologies, not only in oncology and not only in children but also in adults.

__

(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.